These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22189138)

  • 1. Synthesis of novel histamine H4 receptor antagonists.
    Lane CA; Hay D; Mowbray CE; Paradowski M; Selby MD; Swain NA; Williams DH
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1156-9. PubMed ID: 22189138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the G-protein-coupled receptor 119: a conformation-based hypothesis for understanding agonist response.
    McClure KF; Darout E; Guimarães CR; DeNinno MP; Mascitti V; Munchhof MJ; Robinson RP; Kohrt J; Harris AR; Moore DE; Li B; Samp L; Lefker BA; Futatsugi K; Kung D; Bonin PD; Cornelius P; Wang R; Salter E; Hornby S; Kalgutkar AS; Chen Y
    J Med Chem; 2011 Mar; 54(6):1948-52. PubMed ID: 21361292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aminoalkoxybenzyl pyrrolidines as novel human urotensin-II receptor antagonists.
    Jin J; Dhanak D; Knight SD; Widdowson K; Aiyar N; Naselsky D; Sarau HM; Foley JJ; Schmidt DB; Bennett CD; Wang B; Warren GL; Moore ML; Keenan RM; Rivero RA; Douglas SA
    Bioorg Med Chem Lett; 2005 Jul; 15(13):3229-32. PubMed ID: 15936190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
    Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
    J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of a series of potent and selective human H4 antagonists using ligand efficiency and libraries to explore structure-activity relationship (SAR).
    Masood MA; Selby MD; Bell AS; Mansfield AC; Gardner M; Smith GF; Lane C; Kenyon-Edwards H; Osborne R; Jones RM; Liu WL; Brown CD; Clarke N; Perrucio F; Mowbray CE
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6591-5. PubMed ID: 21955944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The first potent and selective non-imidazole human histamine H4 receptor antagonists.
    Jablonowski JA; Grice CA; Chai W; Dvorak CA; Venable JD; Kwok AK; Ly KS; Wei J; Baker SM; Desai PJ; Jiang W; Wilson SJ; Thurmond RL; Karlsson L; Edwards JP; Lovenberg TW; Carruthers NI
    J Med Chem; 2003 Sep; 46(19):3957-60. PubMed ID: 12954048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The discovery of potent antagonists of NPBWR1 (GPR7).
    Anthony Romero F; Hastings NB; Moningka R; Guo Z; Wang M; Di Salvo J; Lei Y; Trusca D; Deng Q; Tong V; Terebetski JL; Ball RG; Ujjainwalla F
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1014-8. PubMed ID: 22197390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (σ2) receptor ligands.
    Banister SD; Rendina LM; Kassiou M
    Bioorg Med Chem Lett; 2012 Jun; 22(12):4059-63. PubMed ID: 22607684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and hit-to-lead exploration of a novel series of histamine H4 receptor inverse agonists.
    Cramp S; Dyke HJ; Higgs C; Clark DE; Gill M; Savy P; Jennings N; Price S; Lockey PM; Norman D; Porres S; Wilson F; Jones A; Ramsden N; Mangano R; Leggate D; Andersson M; Hale R
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2516-9. PubMed ID: 20299215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of the amine terminus in a novel series of 1,2,4-triazolo-3-yl-azabicyclo[3.1.0]hexanes as selective dopamine D3 receptor antagonists.
    Micheli F; Arista L; Bertani B; Braggio S; Capelli AM; Cremonesi S; Di-Fabio R; Gelardi G; Gentile G; Marchioro C; Pasquarello A; Provera S; Tedesco G; Tarsi L; Terreni S; Worby A; Heidbreder C
    J Med Chem; 2010 Oct; 53(19):7129-39. PubMed ID: 20839775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for treatment of sleep disorders.
    Di Fabio R; Pellacani A; Faedo S; Roth A; Piccoli L; Gerrard P; Porter RA; Johnson CN; Thewlis K; Donati D; Stasi L; Spada S; Stemp G; Nash D; Branch C; Kindon L; Massagrande M; Poffe A; Braggio S; Chiarparin E; Marchioro C; Ratti E; Corsi M
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5562-7. PubMed ID: 21831639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and optimization of (R)-prolinol-derived agonists of the Growth Hormone Secretagogue receptor (GHSR).
    Zhai W; Flynn N; Longhi DA; Tino JA; Murphy BJ; Slusarchyk D; Gordon DA; Pendri A; Shi S; Stoffel R; Ma B; Sofia MJ; Gerritz SW
    Bioorg Med Chem Lett; 2008 Sep; 18(18):5083-6. PubMed ID: 18722770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-Aryl-3-pyrrolidinylpyridines as mGlu5 receptor negative allosteric modulators.
    Weiss JM; Jimenez HN; Li G; April M; Uberti MA; Bacolod MD; Brodbeck RM; Doller D
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4891-9. PubMed ID: 21757343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pyrrolidin-3-yl-N-methylbenzamides as potent histamine 3 receptor antagonists.
    Zhou D; Gross JL; Sze JY; Adedoyin AB; Bowlby M; Di L; Platt BJ; Zhang G; Brandon N; Comery TA; Robichaud AJ
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5957-60. PubMed ID: 21843941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, stereochemistry and antioxidant properties of various 7-alkylated 2,4-diaryl-3-azabicyclo[3.3.1]nonan-9-ones.
    Park DH; Venkatesan J; Kim SK; Parthiban P
    Bioorg Med Chem Lett; 2012 Sep; 22(18):6004-9. PubMed ID: 22884407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.
    Bezençon O; Bur D; Weller T; Richard-Bildstein S; Remen L; Sifferlen T; Corminboeuf O; Grisostomi C; Boss C; Prade L; Delahaye S; Treiber A; Strickner P; Binkert C; Hess P; Steiner B; Fischli W
    J Med Chem; 2009 Jun; 52(12):3689-702. PubMed ID: 19358611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and characterization of pyrrolidine diastereoisomers as potent functional agonists and antagonists of the human melanocortin-4 receptor.
    Chen C; Jiang W; Tran JA; Tucci FC; Fleck BA; Markison S; Wen J; Madan A; Hoare SR; Foster AC; Marinkovic D; Chen CW; Arellano M; Saunders J
    Bioorg Med Chem Lett; 2008 Jan; 18(1):129-36. PubMed ID: 18032040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges of drug discovery in novel target space. The discovery and evaluation of PF-3893787: a novel histamine H4 receptor antagonist.
    Mowbray CE; Bell AS; Clarke NP; Collins M; Jones RM; Lane CA; Liu WL; Newman SD; Paradowski M; Schenck EJ; Selby MD; Swain NA; Williams DH
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6596-602. PubMed ID: 21920751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the histamine H4 receptor binding site. Part 1. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives.
    Smits RA; Lim HD; Stegink B; Bakker RA; de Esch IJ; Leurs R
    J Med Chem; 2006 Jul; 49(15):4512-6. PubMed ID: 16854056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.